PDF The Ischemic Heart

Free download. Book file PDF easily for everyone and every device. You can download and read online The Ischemic Heart file PDF Book only if you are registered here. And also you can download or read online all Book PDF file that related with The Ischemic Heart book. Happy reading The Ischemic Heart Bookeveryone. Download file Free Book PDF The Ischemic Heart at Complete PDF Library. This Book have some digital formats such us :paperbook, ebook, kindle, epub, fb2 and another formats. Here is The CompletePDF Book Library. It's free to register here to get Book file PDF The Ischemic Heart Pocket Guide.

Heart muscle disease cardiomyopathy caused by silent ischemia is among the more common causes of heart failure in the United States. Silent ischemia has no symptoms. But researchers have found that if you have episodes of noticeable chest pain, you may also have episodes of silent ischemia. Treatment for ischemia is similar to that for any form of cardiovascular disease and usually begins with the following lifestyle changes:. Your doctor may give you aspirin, anticoagulants, or other blood-thinning agents to prevent blood clots from forming. Oxygen may be given to increase the oxygen content of the blood still flowing through your heart.

Painkillers may be used for pain. Some patients take medicines that slow their heart rate, open and relax their blood vessels, and otherwise reduce the burden on the heart. Most patients respond well to these medicines. This study provides a good overview of the emerging molecular imaging radiotracers that can be used to study myocardial inflammation following ischemia.

Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction. Biomed Rep. Avkiran M. J Card Surg. Laitinen I, et al. Walls MC, et al. Myocardial edema imaging in acute coronary syndromes. J Magn Reson Imaging. Why is the subendocardium more vulnerable to ischemia? A new paradigm. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.

Eur Heart J. Reimer KA, et al. The wavefront phenomenon of ischemic cell death.

Silent Ischemia and Ischemic Heart Disease | American Heart Association

Myocardial infarct size vs duration of coronary occlusion in dogs. Transmural progression of necrosis within the framework of ischemic bed size myocardium at risk and collateral flow. Lab Investig. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. Heusch G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning.

Myocardial reperfusion injury. N Engl J Med. Zhao ZQ, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Dutta P, Nahrendorf M. Monocytes in myocardial infarction. Arterioscler Thromb Vasc Biol. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. Jung K, et al. Endoscopic time-lapse imaging of immune cells in infarcted mouse hearts.

Circ Res. Ducharme A, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction.

Cleutjens JP, et al. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res. Blankesteijn WM, et al. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand. Ertl G, Frantz S. Healing after myocardial infarction. Ammirati E, et al. Barron HV, et al.

J Am Coll Cardiol. Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. This clinical trial provides evidence that anti-inflammatory therapy modulating the interleukin-6 signalling pathway is associated with reduced cardiovascular event rates, independent of lipid lowering therapy. Malarstig A, et al. Raised interleukin is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Padfield GJ, et al. Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction: a first in human study.

Kempf T, et al.

Treatment of Ischaemic Heart Disease

GDF is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. SENSitivity Encoding scheme. Magn Reson Med. Matthaei D, et al. Cardiac and vascular imaging with an MR snapshot technique. Hammer-Hansen S, et al. Early gadolinium enhancement for determination of area at risk: a preclinical validation study. Knott, K. J Magn Reson Imaging, Kotecha, T. Khaw BA, et al. Myocardial infarct imaging of antibodies to canine cardiac myosin with indiumdiethylenetriamine pentaacetic acid. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody.

Sosnovik DE, et al. Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circ Cardiovasc Imaging. Molecular MRI of cardiomyocyte apoptosis with simultaneous delayed-enhancement MRI distinguishes apoptotic and necrotic myocytes in vivo: potential for midmyocardial salvage in acute ischemia. Ye D, et al. Caspase-responsive smart gadolinium-based contrast agent for magnetic resonance imaging of drug-induced apoptosis. Chem Sci. Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Harris TD, et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm. Haubner R, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. Bioconjug Chem. Higuchi T, et al.

1. Introduction

Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Makowski MR, et al. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Anderson SA, et al. Magnetic resonance contrast enhancement of neovasculature with alpha v beta 3 -targeted nanoparticles. Lavin B, et al. MRI with gadofosveset: a potential marker for permeability in myocardial infarction. Kwong RY, et al.

Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Cardiac magnetic resonance imaging as a prognostic tool in patients with nonischemic cardiomyopathy. Hosp Pract Neilan TG, et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. Kim RJ, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. Haaf P, et al.

Cardiac T1 mapping and extracellular volume ECV in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. Moon JC, et al. Helm PA, et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Protti A, et al. J Am Heart Assoc.

Wildgruber M, et al.

Assessment of myocardial infarction and postinfarction scar remodeling with an elastin-specific magnetic resonance agent. Ramos IT, et al. Simultaneous assessment of cardiac inflammation and extracellular matrix remodeling after myocardial infarction. Phinikaridou, A. Circ Cardiovasc Imaging, Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart.

1 Introduction

Su H, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Dutta P, et al. Myocardial infarction accelerates atherosclerosis. Ruehm SG, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits.

Durand E, et al. Magnetic resonance imaging of ruptured plaques in the rabbit with ultrasmall superparamagnetic particles of iron oxide. J Vasc Res. Morishige K, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Schmitz SA, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Investig Radiol. Sigovan M, et al. Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model.

Smith BR, et al. Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles SPIONs contrast particles for magnetic resonance imaging MRI. Biomed Microdevices. Kooi ME, et al.

Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Tang TY, et al.


Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. Correlation of carotid atheromatous plaque inflammation with biomechanical stress: utility of USPIO enhanced MR imaging and finite element analysis. Semple S, et al. PubMedCentral Google Scholar.

Investigators MRS. Aortic wall inflammation predicts abdominal aortic aneurysm expansion, rupture, and need for surgical repair. Flogel U, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Rashid I, et al. Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque. Chen JW, et al. Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis.

Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Amirbekian V, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI.

Yamakoshi Y, et al. Chem Commun Camb. P11 developing new targeted molecular contrast agents for imaging inflammation of vulnerable plaques. Zhuang H, Codreanu I. J Biomed Res. Lee WW, et al. Thackeray JT, et al. Clinically relevant strategies for lowering cardiomyocyte glucose uptake for 18F-FDG imaging of myocardial inflammation in mice.

Tahara N, et al. Targeting amino acid metabolism for molecular imaging of inflammation early after myocardial infarction.

related stories

Morooka M, et al. Li X, et al. Lapa C, et al.

Int J Cardiol. Molecular imaging of the chemokine receptor CXCR4 after acute myocardial infarction.